DYN has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
DYN has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Dyne Therapeutics's total inventories for the quarter that ended in Mar. 2024 was $0.00 Mil. Dyne Therapeutics's average total inventories from the quarter that ended in Dec. 2023 to the quarter that ended in Mar. 2024 was $0.00 Mil.
In Ben Graham's calculation of Net-Net Working Capital, inventory is only considered worth half of its book value. Dyne Therapeutics's Net-Net Working Capital per share for the quarter that ended in Mar. 2024 was $4.70.
Days Inventory indicates the number of days of goods in sales that a company has in the inventory.
Inventory Turnover measures how fast the company turns over its inventory within a year.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
The historical data trend for Dyne Therapeutics's Total Inventories can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Dyne Therapeutics Annual Data | |||||||||||||||
Trend | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||
Total Inventories | Get a 7-Day Free Trial | - | - | - | - | - |
Dyne Therapeutics Quarterly Data | ||||||||||||||||||||
Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | |
Total Inventories | Get a 7-Day Free Trial | - | - | - | - | - |
Total Inventories includes the raw materials, work-in-process goods and completely finished goods of a company. It is a portion of a company's current assets.
Dyne Therapeutics (NAS:DYN) Total Inventories Explanation
Inventory control is an important part of business operation. If a company does not have enough inventory, it may not be able to meet customers' required delivery time. If it has too much inventory, the cost of holding the inventory can be high.
1. In Ben Graham's calculation of Net-Net Working Capital (NNWC), inventory is only considered worth half of its book value.
Dyne Therapeutics's Net-Net Working Capital Per Share for the quarter that ended in Mar. 2024 is
Net-Net Working Capital Per Share (Q: Mar. 2024 ) | |||||||
= | (Cash And Cash Equivalents | + | 0.75 * Accounts Receivable | + | 0.5 * Total Inventories | - | Total Liabilities |
- | Preferred Stock | - | Minority Interest) | / | Shares Outstanding (EOP) | ||
= | (453.547 | + | 0.75 * 0 | + | 0.5 * 0 | - | 44.224 |
- | 0 | - | 0) | / | 87.0897 | ||
= | 4.70 |
2. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.
Dyne Therapeutics's Days Inventory for the three months ended in Mar. 2024 is calculated as:
Days Inventory | = | Average Total Inventories (Q: Mar. 2024 ) | / | Cost of Goods Sold (Q: Mar. 2024 ) | * | Days in Period |
= | 0 | / | 0 | * | 365 / 4 | |
= |
3. Inventory Turnover measures how fast the company turns over its inventory within a year.
Dyne Therapeutics's Inventory Turnover for the quarter that ended in Mar. 2024 is calculated as
Inventory Turnover | = | Cost of Goods Sold (Q: Mar. 2024 ) | / | Average Total Inventories (Q: Mar. 2024 ) |
= | 0 | / | 0 | |
= | N/A |
4. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Dyne Therapeutics's Inventory to Revenue for the quarter that ended in Mar. 2024 is calculated as
Inventory-to-Revenue | = | Average Total Inventories (Q: Mar. 2024 ) | / | Revenue (Q: Mar. 2024 ) |
= | 0 | / | 0 | |
= |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Manufacturers with durable competitive advantages have the advantage that the products they sell do not change, and therefore will never become obsolete. Buffett likes this advantage.
When identifying manufacturers with durable competitive advantage, look for inventory and net earnings that rise correspondingly. This indicates that the company is finding profitable ways to increase sales which called for an increase in inventory.
Manufacturers with inventories that spike up and down are indicative of competitive industries subject to boom and bust.
Thank you for viewing the detailed overview of Dyne Therapeutics's Total Inventories provided by GuruFocus.com. Please click on the following links to see related term pages.
Dirk Kersten | director, 10 percent owner | C/O FORBION CAPITAL FUND IV COOPERATIEF, GOOMIER 2-35, NAARDEN P7 14111 DC |
Joshua T Brumm | director, officer: See Remarks | ZELTIQ AESTHETICS INC., 4698 WILLOW ROAD SUITE 100, PLEASANTON CA 94588 |
Jonathan Mcneill | officer: See Remarks | C/O DYNE THERAPEUTICS, INC., 830 WINTER STREET, WALTHAM MA 02451 |
Oxana Beskrovnaya | officer: See Remarks | C/O DYNE THERAPEUTICS, INC., 830 WINTER STREET, WALTHAM MA 02451 |
Richard William Scalzo | officer: See Remarks | 25 ALBERTA LANE, HOLLISTON MA 01746 |
Wildon Farwell | officer: Chief Medical Officer | C/O DYNE THERAPEUTICS, INC., 830 WINTER STREET MA 02451 |
Susanna Gatti High | officer: Chief Operating Officer | 75 LORIMER ROAD, BELMONT MA 02141 |
Atlas Venture Associates Opportunity Ii, Lp | 10 percent owner | 300 TECHNOLOGY SQUARE, 8TH FLOOR, CAMBRIDGE MA 02139 |
Atlas Venture Fund Xi, L.p. | 10 percent owner | 400 TECHNOLOGY SQUARE, 10TH FLOOR, CAMBRIDGE MA 02139 |
Jason P Rhodes | director, 10 percent owner | C/O EPIZYME, INC., 400 TECHNOLOGY SQUARE, 4TH FLOOR, CAMBRIDGE MA 02139 |
Atlas Venture Opportunity Fund Ii, L.p. | 10 percent owner | 300 TECHNOLOGY SQUARE, 8TH FLOOR, CAMBRIDGE MA 02139 |
Atlas Venture Associates Opportunity Ii, Llc | 10 percent owner | 300 TECHNOLOGY SQUARE, 8TH FLOOR, CAMBRIDGE MA 02139 |
Carlo Incerti | director | FORBION CAPITAL FUND IV COOPERAITEF U.A., GOOMIER 2-35, NAARDEN P7 1411DC |
Romesh Subramanian | 10 percent owner, officer: Chief Scientific Officer | C/O DYNE THERAPEUTICS, INC., 830 WINTER STREET, WALTHAM MA 02451 |
Cureduchenne Ventures, Llc | 10 percent owner | 1400 QUAIL STREET, SUITE 110, NEWPORT BEACH CA 92660 |
From GuruFocus
By Marketwired • 11-07-2023
By sperokesalga sperokesalga • 05-11-2023
By PurpleRose PurpleRose • 08-04-2022
By Value_Insider Value_Insider • 11-02-2022
By PurpleRose PurpleRose • 07-15-2022
By GuruFocus Research • 01-05-2024
By Stock market mentor Stock market mentor • 01-03-2023
By GuruFocus Research • 06-15-2023
By sperokesalga sperokesalga • 05-02-2023
By sperokesalga sperokesalga • 05-25-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.